

— it is expedient to set the levy for the Commission de la construction du Québec for the year 1997 before 1 January 1997;

WHEREAS it is expedient to approve the Levy Regulation;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Labour:

THAT the Levy Regulation of the Commission de la construction du Québec, attached to this Order in Council, be approved.

MICHEL CARPENTIER,  
*Clerk of the Conseil exécutif*

## Levy Regulation of the Commission de la construction du Québec

An Act respecting labour relations, vocational training and manpower management in the construction industry (R.S.Q., c. R-20, s. 82; 1995, c. 8, s. 40)

**1.** The Levy imposed by the Commission de la construction du Québec for the year 1997, payable by the employer and the employee, is carried out as follows:

*a)* the employer shall pay the Commission a sum equivalent to 0,75 of 1 % of the total remuneration paid to his employees. The independent contractor shall pay a sum equivalent to 0,75 of 1 % of his remuneration as an independent contractor. However, the minimum amount that an employer or an independent contractor is bound to pay per monthly period of work is \$10;

*b)* the employee shall pay a sum equivalent to 0,75 of 1 % of his remuneration to the Commission.

**2.** The employer shall deduct each week, on behalf of the Commission, the levy imposed on each of his employees by retaining it out of each employee's wages.

**3.** The independent contractor shall deduct at the end of each week the prescribed levy by retaining such levy from the remuneration he receives as an independent contractor.

**4.** The employer and the independent contractor shall remit to the Commission not later than the 15<sup>th</sup> of each month the levy due for the preceding monthly period.

**5.** The regulation comes into force as of 1 January 1997.

Gouvernement du Québec

## O.C. 1532-96, 6 December 1996

An Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32)

### Basic prescription drug insurance plan — Amendments

Regulation to amend the Regulation respecting the basic prescription drug insurance plan

WHEREAS under subparagraph 3 of the first paragraph of section 78 of the Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32), the Government may, after consulting the Régie de l'assurance-maladie du Québec, make regulations to determine the cases, conditions and therapeutic indications in and for which the cost of certain medications included in the list drawn up by the Minister of Health and Social Services under section 60 of the Act is covered by the basic prescription drug insurance plan; the conditions may vary according to whether the coverage is provided by the Board or under a group insurance contract or an employee benefit plan;

WHEREAS under section 112 of that Act, the Government may, not later than 31 December 1996, make a regulation under section 78 of the Act even if the regulation has not been published as required by section 8 of the Regulations Act (R.S.Q., c. R-18.1). Such a regulation shall come into force, notwithstanding section 17 of that Act, on the date of its publication in the *Gazette officielle du Québec* or on any later date fixed in the regulation and it may, if it so provides, apply to any class of eligible persons it determines and from any date not prior to 20 June 1996;

WHEREAS by Order in Council 1519-96 dated 4 December 1996, the Government made the Regulation respecting the basic prescription drug insurance plan;

WHEREAS it is expedient to amend that Regulation;

WHEREAS in accordance with section 78 of the Act respecting prescription drug insurance and amending various legislative provisions, the Régie de l'assurance-maladie du Québec has been consulted;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Health and Social Services:

THAT the Regulation to amend the Regulation respecting the basic prescription drug insurance plan, the text of which is attached to this Order in Council, be made.

MICHEL CARPENTIER,  
*Clerk of the Conseil exécutif*

## Regulation to amend the Regulation respecting the basic prescription drug insurance plan

An Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32, s. 78. 1<sup>st</sup> par., subpar. 3)

**1.** The Regulation respecting the basic prescription drug insurance plan, made by Order in Council 1519-96 dated 4 December 1996, is amended by inserting the following after section 2:

“**2.1** The medications provided for in the second paragraph are the subject of the basic plan coverage referred to in the second paragraph of section 8 of the Act respecting prescription drug insurance and amending various legislative provisions, where the following conditions are fulfilled:

(1) in the case of persons whose coverage under the basic plan is provided by the Régie de l'assurance-maladie du Québec, a prior request for authorization, duly completed in accordance with the form prescribed to that effect in the Regulation respecting forms and statements of fees under the Health Insurance Act (R.R.Q., 1981, c. A-29, r. 2) was sent to the Régie;

(2) in the case of persons whose coverage under the basic plan is provided by insurers transacting group insurance or by administrators of private-sector employee benefit plans, a prior request for authorization, if required under the applicable group insurance contract or employee benefit plan, was sent to the insurer or to the administrator of the employee benefit plan, according to the terms and conditions provided for in that contract or plan.

Notwithstanding the foregoing, the medications are covered only for the duration authorized, as the case may be, by the Board, the insurer, or the administrator of the employee benefit plan concerned, if the medications are prescribed for the therapeutic indications stipulated in regard to each of them:

(1) ACYCLOVIR, tab., Avirax, Zovirax:

(a) in immunodeficient patients, for the curative and preventive treatment of severe herpes virus infections;

(b) in immunocompetent patients:

i. for the early treatment of zona, that is, within 48 to 72 hours following the appearance of lesions;

ii. for the suppressive treatment of recurring herpes virus infections, that is, 6 episodes or more per year;

iii. for the curative treatment of severe herpes virus infections;

iv. for the early curative treatment of varicella-zoster infection in patients 13 years of age or older and in children over 12 months suffering from chronic skin diseases or pulmonary disorders or receiving a long-term salicylate-based therapy;

(2) ACYCLOVIR, top. cr., top. oint.: for the local treatment of herpes virus infections in immunodeficient patients;

(3) ALENDRONATE, tab., Fosamax:

(a) for the treatment of fractural postmenopausal osteoporosis;

(b) for the treatment of patients suffering from symptomatic Paget's disease who have an intolerance to or who do not respond to etidronate;

(4) CALCIUM ALGINATE (fibre) dres., Kaltostat: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(5) ALUMINUM (hydroxide), tab, Amphojel: as a phosphate binder in patients suffering from severe renal failure;

(6) ANASTROZOLE, tab., Arimidex: for the treatment of metastatic breast cancer in menopausal woman, after failure of a tamoxifen treatment or when a megestrol acetate treatment causes undesired weight gain;

(7) ANETHOLE TRITHIONE, tab., Sialor: for the treatment of patients suffering from severe xerostomia;

(8) BISACODYL, ent. tab., supp., Bisacolax, Bisacodyl, PMS-Bisacodyl, Apo-Bisocodyl: for the treatment of constipation secondary to opiate analgesics;

(9) BUTORPHANOL (tartrate), nas. sol., Stadol NS: for the nonprophylactic treatment of episodes of migraines in patients for whom treatment with other analgesics or with other drug therapies is ineffective;

(10) CALCIUM (acetate) tab., calcium acetate: as a phosphate binder in patients suffering from severe renal failure;

(11) CALCIUM (carbonate and others), oral forms, Apo-Cal, Cal-500: as a calcium supplement for patients suffering from hypoparathyroidism, lactase deficiency, malabsorption, or severe chronic renal failure;

(12) CALCIUM (gluconate)/CALCIUM (glucoheptanate), oral sol., Calcium Stanley, Calcium-Rougier: as a calcium supplement for children suffering from bovine protein or lactose intolerance;

(13) CAPSAICIN, top. cr., Capsaicin cream, Capsaicin mild, Capsaicin regular, Capsaicin Forte, Capsaicin-HP cream: for the treatment of pain caused by episodes of herpes zoster infection or related to peripheral neuropathies;

(14) SODIUM CHLORIDE, dres., Mesalt: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(15) SODIUM CITRATE/SODIUM LAURYL SULFOACETATE, rect. sol., Microlax: for the treatment of constipation secondary to opiate analgesics;

(16) CLINDAMYCIN (phosphate), top. sol., Dalacin-T: for the treatment of acne pustulosa in patients for whom topical erythromycin is ineffective or poorly tolerated;

(17) CLOZAPINE, tab., Clozaril: for the symptomatic treatment of schizophrenia in patients for whom an appropriate treatment with antipsychotic drugs has proven ineffective or has caused intolerable side effects, preventing administration of an effective dose;

(18) CYCLOSPORINE, caps, oral sol., Sandimmune, Sandimmune Neoral:

(a) for the prevention of the rejection of a graft subsequent to an organ transplant and for the treatment of rejection in patients having already received other immunosuppressants;

(b) for the prevention of the rejection of a graft subsequent to a bone marrow transplant and for the prevention or treatment of the graft-vs-host reaction (GVHR);

(c) for the treatment of persons suffering from severe psoriasis and for whom conventional therapies have proven ineffective or inadequate or where the severity of the disease justifies the risks of treatment with cyclosporine;

(d) for the treatment of persons suffering from severe progressive rheumatoid arthritis where slow-acting antirheumatismal agents have been inadequate or ineffective;

(e) for the treatment of persons who have a nephrotic syndrome, are steroid-dependent or are resistant to steroids, attributable to a glomerulopathy;

(19) DESMOPRESSIN (acetate), tab., DDAVP: for the treatment of patients suffering from diabetes insipidus who are unable to use a nasal vaporizer or a desmopressin nasal solution;

(20) DICLOFENAC SODIUM, oph. sol., Voltaren Ophtha: for the treatment of eye inflammation in patients for whom ophthalmic corticosteroids are not indicated;

(21) DIPYRIDAMOLE, tab., Apo-Dipyridamole-FC, APO-Dipyridmole-SC, Novo-Dipiradol, Dipyridamole, Persantine: for the prevention of thromboembolisms in patients who have valvular or vascular prostheses or who have undergone a bypass operation with a vein graft;

(22) DOCUSATE CALCIUM, caps., PMS-Docusate-Calcium, Docusate Calcium, Novo-Docusate Calcium: for the treatment of constipation secondary to opiate analgesics;

(23) DOCUSATE SODIUM, caps., syr., oral sol., Colax-S, Regulex, Selax, Novo-Docusate, Docusate Sodium, PMS-Docusate Sodium, PMS-Docusale, Soflax: for the treatment of constipation secondary to opiate analgesics;

(24) ALFA DORNASE, nebulizer, Pulmozyme: for the treatment of patients over 5 years of age suffering from cystic fibrosis and whose forced vital capacity is more than 40 percent of the predicted value;

(25) DORZOLAMIDE (hydrochloride), oph. sol., Trusopt:

(a) for the adjuvant treatment of glaucoma where treatment with a beta-blocker provides insufficient control of ocular tension;

(b) for the treatment of glaucoma using monotherapy when there is a contraindication for or intolerance to a beta-blocker;

(26) ALFA EPOETINE, inj. sol., Eprex:

(a) in dialysis patients or before the beginning of dialysis for the treatment of symptomatic anemia related to severe chronic renal failure;

(b) for the treatment of nonhemolytic symptomatic anemia in cancer patients or in patients treated with zidovudine after the dosage of this medication has been reassessed in the context of anemia and having no iron, folic acid or vitamin B12 deficiency.

(27) ESTRADIOL-17 $\beta$ , skin patch, Estraderm 25, Estraderm 50, Estraderm 100, Vivelle 37.5, Vivelle 50, Vivelle 75, Vivelle 100: for patients unable to take estrogens orally because of thromboembolic disorders or who have an intolerance to oral estrogens;

(28) ESTRADIOL-17 $\beta$ /NORETHINDRONE (acetate), skin patch, Estracomb: for patients unable to take estrogens orally because of thromboembolic disorders or who have an intolerance to oral estrogens;

(29) FAMCICLOVIR, tab., Famvir: for the early treatment of zona, that is, within 48 to 72 after the appearance of lesions;

(30) FENTANYL, skin patch, Duragesic: for relief of pain in patients intolerant to oral morphine preparations or unable to swallow because of a digestive pathology, and who do not have a painful unstable syndrome or too rapid a progression of symptoms in the advanced stage of a cancer;

(31) FILGRASTIM, inj. sol., Neupogen:

(a) during chemotherapy treatment of children suffering from a solid tumor;

(b) for the treatment of patients suffering from:

i. severe neutropenia (number of neutrophils under  $0.5 \times 10^9/L$ ) occurring in the first cycles of chemotherapy;

ii. neutropenia liable to cause a delay in the administration of chemotherapy or an unacceptable dosage reduction;

iii. severe bone marrow suppression while awaiting a curative treatment by means of a bone marrow transplant or antithymocyte serum, and who develop a severe infection;

iv. congenital or hereditary neutropenia with a neutrophil count of less than  $0.5 \times 10^9/L$ , and who develop severe recurrent infections;

(c) for the treatment of HIV-infected patients suffering from neutropenia secondary to antiretroviral medication or ganciclovir who are unable to tolerate foscarnet and whose number of neutrophils remain under  $0.5 \times 10^9$

L, despite temporary stopping of medication or dosage reduction;

(32) FLUCONAZOLE, oral susp., Diflucan:

(a) for the treatment of oropharyngeal candidiasis in patients for whom conventional therapy is ineffective or poorly tolerated;

(b) for the treatment of esophageal candidiasis;

(33) NUTRITIVE FORMULAS — CASEIN-BASED (INFANTS AND CHILDREN) Alimentum, Nutramigen, Pregestimil: food preparation for infants and children:

(a) allergic to complete milk proteins;

(b) requiring a lactose-free diet for galactosemia;

(c) suffering from persistent diarrhea or other severe gastrointestinal disorders;

(34) NUTRITIVE FORMULAS — POLYMERIZED GLUCOSE, Polycose:

(a) for total oral feeding and enteral feeding of patients requiring liquid nutritive formulas as their sole source of nutrition in presence of:

i. esophageal dysfunction or dysphagia;

ii. digestive or malabsorption disorders;

(b) for children suffering from Crohn's disease;

(c) for patients suffering from cystic fibrosis;

(35) NUTRITIVE FORMULAS — FRACTIONATED COCONUT OIL, MCT: for the nutritional management of persons who do not effectively digest or absorb long-chain fatty foods;

(36) NUTRITIVE FORMULAS — SKIM MILK/COCONUT OIL, Portagen: for the nutritional management of persons who do not effectively digest or assimilate long-chain fatty foods;

(37) NUTRITIVE FORMULAS — MONOMERIC, Citrisource, Criticare HN, Hepatic-Acid II, Peptamen, Peptamen Jr, Sandosource Peptide, Tolerex, Vital HN, Vivonex Pediatric, Vivonex Plus, Vivonex T.E.N.:

(a) for total oral feeding and enteral feeding of patients requiring liquid nutritive formulas as their sole source of nutrition in presence of:

- i. esophageal dysfunction or dysphagia;
- ii. maldigestion or malabsorption disorders;

(b) for children suffering from Crohn's disease;

(c) for patients suffering from cystic fibrosis;

(38) NUTRITIVE FORMULAS — POLYMERIC WITH RESIDUES, Advera, Compleat Modified, Glucerna, Isocal with fibre, Jevity, Nubasic fibres, Nutren with fibre, Nutrisource, Nutrisource HN, Pediasure with fibre:

(a) for total oral feeding and enteral feeding of patients requiring liquid nutritive formulas as their sole source of nutrition in presence of:

- i. esophageal dysfunction or dysphagia;
- ii. maldigestion or malabsorption disorders;

(b) for children suffering from Crohn's disease;

(c) for patients suffering from cystic fibrosis;

(39) NUTRITIVE FORMULAS — LOW-RESIDUE POLYMERIC, Ensure Hyper-Protéine, Isocal, Isocal HN, Isosource, Isosource HN, Isosource VHN, Isotein HN, Lipisorb, Méritene, NuBasics, NuBasics Plus, NuBasics VHP, Nutren 1, Nutren 1.5, Nutren 2, Osmolite HN, Pediasure, Promote, Pulmocare, Resource, Resource Plus, Resource for children:

(a) for total oral feeding and enteral feeding of patients requiring liquid nutritive formulas as their sole source of nutrition in presence of:

- i. esophageal dysfunction or dysphagia;
- ii. maldigestion or malabsorption disorders;

(b) for children suffering from Crohn's disease;

(c) for patients suffering from cystic fibrosis;

(40) NUTRITIVE FORMULAS — PROTEINS/ CARBOHYDRATES & LIPIDS (INFANTS AND CHILDREN), Similac PM 60/40: food preparation for premature babies and infants requiring products low in mineral content;

(41) GANCICLOVIR, caps., Cytovene: for the maintenance treatment of cytomegalovirus (CMV) retinitis in immunodeficient patients;

(42) GRANISETRON (hydrochloride), tab., Kytril: as an antiemetic:

(a) on the first day of a highly emetic chemotherapy or radiotherapy treatment;

(b) in children during a highly emetic chemotherapy or radiotherapy treatment;

(c) during chemotherapy or radiotherapy in patients for whom conventional therapy is ineffective or poorly tolerated;

(43) MINERAL OIL, oral gel, Liq. Liq. (rect.), Lansoyl without sugar, Mineral oil, Fleet enema: for the treatment of constipation secondary to opiate analgesics;

(44) HYDROXYPROPYL METHYCELLULOSE, oph. sol., Eyelube, Isopto Tears: for the treatment of keratoconjunctivitis sicca;

(45) HYDROXYPROPYL METHYCELLULOSE/ DEXTRAN 70, oph. sol., Tears Naturelle, Tears Naturelle II: for the treatment of keratoconjunctivitis sicca;

(46) IDARUBICIN (hydrochloride), caps., Idamycin: for the treatment of acute myelocytic leukemia in adults;

(47) BETA INTERFERON, 1-B, inj. pd., Betaseron: for the treatment of patients suffering from cyclic remitting multiple sclerosis who are capable of walking, although with assistance, and who have had 2 or more episodes of the disease within the last 2 years;

(48) KETOROLAC (tromethamine), oph. sol., Acular: for the treatment of eye inflammation in patients for whom ophthalmic corticosteroids are not indicated;

(49) LACTULOSE, syr., Cephulac, Chronulac, Comalose-R, Lactulax, PMS-Lactulose:

(a) for the treatment of hepatic encephalopathy;

(b) for the treatment of constipation secondary to opiate analgesics;

(50) MAGNESIUM (hydroxide), oral susp., Milk of magnesia: for the treatment of constipation secondary to opiate analgesics;

(51) MEGESTROL (acetate) tab., Apo-megestrol, Linmegestrol, Megace, Nu-Megestrol:

(a) for the treatment of cancer;

(b) for hormone replacement therapy in patients having suffered from breast cancer;

(52) METRONIDAZOLE, vag. gel., Nidagel: for the treatment of bacterial vaginosis in pregnant women;

(53) MIDODRINE (hydrochloride), tab., Amatine:

(a) for the treatment of primary idiopathic orthostatic hypotension in patients for whom the conventional treatment is insufficient or is contraindicated;

(b) for the treatment of secondary idiopathic orthostatic hypotension in patients suffering from Parkinson's disease;

(54) MINOCYCLINE (hydrochloride), caps, Apo-Minocycline, Minocin, Minocycline-100, Syn-Minocycline: for the treatment of acne or other superficial skin infections in patients for whom tetracycline would be indicated but is ineffective or poorly tolerated;

(55) OCTREOTIDE, s.c. inj. sol., Sandostatin:

(a) for the control of symptoms in patients suffering from carcinoid metastases and intestinal tumors secreting vasoactive peptides;

(b) for the treatment of acromegaly;

(56) ONDANSETRON (hydrochloride), tab., Zofran: as an antiemetic:

(a) on the first day of a highly emetic chemotherapy or radiotherapy treatment;

(b) in children during a highly emetic chemotherapy or radiotherapy treatment;

(c) during chemotherapy or radiotherapy in patients for whom conventional therapy is ineffective or poorly tolerated;

(57) CARBOXYMETHYL CELLULOSE, dressing, Aquacel, Aquacel Hydrofiber: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(58) ACTIVATED CHARCOAL/SILVER DRESSING, dres., Actosorb Plus: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(59) COLLAGEN/ALGINATE DRESSING, dres., Fibracol,: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(60) HYDROCOLLOIDAL DRESSING, dres., Combiderm ACD, DuoDERM CGF Extra-Mince, DorDERM CGF Bordé, Tegaserb, Cutinova Hydro, DuoDERM, DuoDERM CGF, Tielle: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(61) HYDROCOLLOIDAL/ALGINATE DRESSING, dres., DermaSorb: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(62) HYDROGEL DRESSING, dres., NU-GEL: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(63) SEMIPERMEABLE DRESSINGS, dres., Alldress: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(64) PARAFFIN/MINERAL OIL, oph. oint., Peralube, Duratears: for the treatment of keratoconjunctivitis sicca;

(65) PENTOXIFYLLINE, tab. L.A., Trental: for the treatment of patients suffering from a trophic ulcer;

(66) MONOBASIC SODIUM PHOSPHATE/DIBASIC SODIUM PHOSPHATE, rect. sol., ped. rect. sol., Fleet, Enemol, Fleet Pediatric: for the treatment of constipation secondary to opiate analgesics;

(67) HYDROPHILIC POLYURETHANE, dres., Allebyn, Allebyn adhesive, Allebyn circular, Hydrasorb: for the treatment of patients suffering from serious burns or cutaneous ulcers;

(68) POLYVINYL (alcohol), oph. sol., PMS-Artificial Tears, R.O. Yeux secs: for the treatment of keratoconjunctivitis sicca;

(69) POLYVINYL(alcohol)/POLYETHYLENE GLYCOL 6000, oph. sol, Hypotears: for the treatment of keratoconjunctivitis sicca;

(70) POLYVINYL(alcohol)/POVIDONE, oph. sol., Tear Drops, PMS-Artificial: for the treatment of keratoconjunctivitis sicca;

(71) SENNOSIDES A&B, tab., gran., supp., Sennosides, PMS-Sennosides, Riva-Sennosides, Sennatabs, Senokot: for the treatment of constipation secondary to opiate analgesics;

(72) SOMATOTROPHIN, inj. pd., Humatrop, Nutropin, Saizen:

(a) for the treatment of children suffering from delayed growth caused by insufficient secretion of the endogenous growth hormone, except children who are carriers of a Turner's syndrome or are suffering from achondroplasia or from delayed growth of a genetic or familial type, children whose bone age has reached 15 years for girls and 16 years for boys, and children whose growth rate falls below 4 cm per year, evaluated on two consecutive visits at a 3-month interval, where they meet the following criteria:

i. untermiated growth and growth rate for their bone age less than the 25<sup>th</sup> percentile, calculated over at least a one-year period, except in the case of young children suffering from hyperglycemia secondary to a growth hormone deficiency, to whom the one-year observation period does not apply;

ii. serum concentration of somatotrophin less than 8 ng/mL measured by two pharmacological tests, or serum concentration between 8 and 10 ng/mL if the tests are repeated twice at a 6-month interval;

(b) for the treatment of children suffering from delayed growth related to chronic renal failure until renal transplant;

(73) SORBITOL, oral pd., Sorbital Rougier: for the treatment of constipation secondary to opiate analgesics;

(74) SUMATRIPTAN (succinate) tab., s.c. inj. sol., Imitrex: for the treatment of nonprophylactic episodes of migraines in patients for whom treatment with analgesics or with other drug therapies is ineffective;

(75) TOCOPHERYL (d-alpha acetate), caps., oral sol., Aquasol E: for the treatment of neurological manifestations associated with the malabsorption of vitamin E;

(76) TRETINOIN, top. cr., top. gel and top. sol., Vitamin A Acid Crème, Stieva-A, Retin-A, Vitinoin, Stieva-A Forte, Vitamin A Acid Gel Doux, Vitamin-A Acid Gel: for the treatment of acne;

(77) VALACYCLOVIR (hydrochloride) tab., Valtrex: for the early treatment of zona, that is, within 48 to 72 hours after the appearance of lesions.”

**2.** This Regulation replaces sections 67.1 and 67.2 of the Regulation respecting the application of the Health Insurance Act (R.R.Q., 1981, c. A-29, r. 1).

**3.** This Regulation comes into force on 1 January 1997.

Gouvernement du Québec

## O.C. 1563-96, 11 December 1996

Health Insurance Act  
(R.S.Q., c. A-29)

### Regulation — Amendment

Regulation to amend the Regulation respecting the application of the Health Insurance Act

WHEREAS under subparagraph *b* of the first paragraph of section 69 of the Health Insurance Act (R.S.Q., c. A-29), the Government may, after consultation with the Board or upon its recommendation, make regulations to determine among the services contemplated in section 3 those which are not to be deemed insured services, and how often some of those contemplated in subparagraph *c* of the first paragraph or in the second paragraph of section 3 may be rendered in order to remain insured services;

WHEREAS the Government made the Regulation respecting the application of the Health Insurance Act (R.R.Q., 1981, c. A-29, r. 1) and it is expedient to amend it;

WHEREAS in accordance with sections 10 and 13 of the Regulations Act (R.S.Q., c. R-18.1), a draft of the Regulation to amend the Regulation respecting the application of the Health Insurance Act was published in Part 2 of the *Gazette officielle du Québec* of 20 November 1996 with a notice that it could be made by the Government upon the expiry of 15 days following that publication;

WHEREAS the Régie de l'assurance-maladie du Québec has been consulted on those amendments;

WHEREAS the 15-day period has expired;

WHEREAS it is expedient to make the Regulation without amendment;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Health and Social Services:

THAT the Regulation to amend the Regulation respecting the application of the Health Insurance Act, attached to this Order in Council, be made.

MICHEL CARPENTIER,  
*Clerk of the Conseil exécutif*